The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs

被引：0
|
作者：
Szpechcinski, A. [1 ]
Bryl, M. [2 ]
Wojda, E. [1 ]
Czyzewicz, G. [3 ]
Swiniuch, D. [4 ]
Szwiec, M. [5 ]
Ramlau, R. [4 ]
Sliwinski, P. [1 ]
Barinow-Wojewodzki, A. [2 ]
Chorostowska-Wynimko, J. [1 ]
机构：
[1] Inst TB & Lung Dis, Warsaw, Poland
[2] EJ Zeyland Wielkopolska Ctr Pulmonol & Thorac Sur, Poznan, Poland
[3] John Paul II Specialist Hosp, Krakow, Poland
[4] Med Univ Poznan, Poznan, Poland
[5] Univ Hosp Zielona Gora, Zielona Gora, Poland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; EGFR mutations; liquid biopsy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-07
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [41] Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
    Guowei Zhang
    Ruirui Cheng
    Zengli Zhang
    Tao Jiang
    Shengxiang Ren
    Zhiyong Ma
    Sha Zhao
    Caicun Zhou
    Jun Zhang
    Scientific Reports, 7
  • [42] Progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring EGFR mutation
    Yoshida, Tatsuya
    Yoh, Kiyotaka
    Goto, Koichi
    Matsumoto, Shingo
    Umemura, Shigeki
    Niho, Seiji
    Ohmatsu, Hironobu
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
    Zhang, Guowei
    Cheng, Ruirui
    Zhang, Zengli
    Jiang, Tao
    Ren, Shengxiang
    Ma, Zhiyong
    Zhao, Sha
    Zhou, Caicun
    Zhang, Jun
    SCIENTIFIC REPORTS, 2017, 7
  • [44] Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
    Huang, Chu-ying
    Wang, Li
    Feng, Cheng-jun
    Yu, Ping
    Cai, Xiao-hong
    Yao, Wen-xiu
    Xu, Yong
    Liu, Xiao-ke
    Zhu, Wen-jiang
    Wang, Yan
    Zhou, Jin
    Lu, You
    Wang, Yong-sheng
    ONCOTARGET, 2016, 7 (41): : 66480 - 66490
  • [45] EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring
    Wang, Yunlong
    Qiu, Qinggui
    Deng, Xuan
    Wan, Mengchao
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [46] Factors Associated with Symptoms Improvement and HRQoL for First-Line EGFR-TKIs in NSCLC: A Multicenter Prospective SMILE Study
    Wei, Y.
    Huang, W.
    Liu, T.
    Shieh, J.
    Chian, C.
    Wu, M.
    Chang, C.
    Lin, C.
    Ko, J.
    Lin, C.
    Hsia, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2205 - S2206
  • [47] LOSS OF AMPLIFIED EGFR GENE WITH MUTATION AS A NOVEL MECHANISM OF ACQUIRED RESISTANCE TO EGFR-TKIS IN EGFR MUTATED NSCLC CELLS
    Furugaki, K.
    Iwai, T.
    Moriya, Y.
    Fujimoto-Ouchi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 390 - 391
  • [48] Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs
    Oya, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S622 - S622
  • [49] Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT
    Niu, Lishui
    Wu, Honghua
    Gao, Ruihuan
    Chen, Liu
    Wang, Jiangtao
    Duan, Hexin
    Long, Yujiao
    Xie, Yi
    Zhou, Qin
    Zhou, Rongrong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (02)
  • [50] Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC
    Li-Li Deng
    Ge Gao
    Hong-Bin Deng
    Feng Wang
    Zhi-Hui Wang
    Yu Yang
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 2613 - 2624
12345